Gastroparesis is a common GI problem affecting approximately 8 million Americans. The syndrome refers to delayed gastric emptying, in the absence of mechanical obstruction of the stomach, and is associated with a variety of symptoms. Patients with gastroparesis may experience symptoms of: postprandial fullness, nausea, vomiting, particularly vomiting of food ingested several hours previously, upper abdominal distention (bloating), early satiety, and anorexia. Severe symptoms may result in poor nutrition and dehydration resulting in hospitalization.
About Evoke Pharma, Inc.
Evoke Pharma, Inc. is a privately held, specialty pharmaceutical company headquartered in San Diego, CA focused on acquiring and developing products to treat GI disorders and diseases. Evoke's lead product, EVK-001, is currently in Phase 2b for the treatment of the symptoms associated with diabetic gastroparesis. The management team has an established track record of building successful specialty pharmaceutical companies. The company completed a $12 million Series A financing from Domain Associates and Latterell Venture Partners. Evoke holds rights to intellectual property associated with EVK-001 granted by the United States Patent & Trademark Office with expiration dates through 2021.
Further information regarding Evoke is available at www.EvokePharma.com.
Evoke Pharma cautions that statements included in this press release that are not a description of histor
|SOURCE Evoke Pharma, Inc.|
Copyright©2009 PR Newswire.
All rights reserved